Is AMD Stock an All-Time Buy?
Advanced Micro Devices (NASDAQ:AMD) is a high-growth AI stock that…
Buy
75
TOI Quote, Financials, Valuation and Earnings
Last price:
$0.26
Seasonality move
:
-6.55%
Day range:
$0.21 - $0.29
52-week range:
$0.13 - $2.50
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.05x
P/B ratio:
1.30x
Volume:
1.1M
Avg. volume:
3.4M
1-year change:
-86.9%
Market cap:
$20.1M
Revenue:
$324.2M
EPS (TTM):
-$0.78
Analysts' Opinion
-
Consensus RatingThe Oncology Institute has received a consensus rating of --. The company's average rating is a -- based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, The Oncology Institute has an estimated upside of 652.16% from its current price of $0.27.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $0.27.
Fair Value
-
According to the consensus of 0 analysts, The Oncology Institute has 652.16% upside to fair value with a price target of -- per share.
TOI vs. S&P 500
-
Over the past 5 trading days, The Oncology Institute has overperformed the S&P 500 by 40.28% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
The Oncology Institute does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
The Oncology Institute has grown year-over-year revenues for 11 quarters straight. In the most recent quarter The Oncology Institute reported revenues of $99.9M.
Earnings Growth
-
The Oncology Institute has grown year-over-year earnings for 0 quarters straight. In the most recent quarter The Oncology Institute reported earnings per share of -$0.18.
Enterprise value:
64.2M
EV / Invested capital:
0.60x
Price / LTM sales:
0.05x
EV / EBIT:
--
EV / Revenue:
0.17x
PEG ratio (5yr expected):
-0.10x
EV / Free cash flow:
-1.71x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$53.7M
Return On Assets:
-35.44%
Net Income Margin (TTM):
-18.54%
Return On Equity:
-163.45%
Return On Invested Capital:
-53.47%
Operating Margin:
-13.87%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $233.4M | $309.9M | $378.9M | $82M | $99.9M | |
| Gross Profit | $44.8M | $60.8M | $53.7M | $16M | $14.4M | |
| Operating Income | -$97.7M | -$60M | -$63.5M | -$13.9M | -$13.9M | |
| EBITDA | $4.5M | -$62.6M | -$56.1M | -$13.8M | -$12.3M | |
| Diluted EPS | -$0.17 | -$0.86 | -$0.78 | -$0.19 | -$0.18 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | $143.6M | $152.7M | $116.4M | |
| Total Assets | -- | -- | $283.8M | $218.4M | $179.2M | |
| Current Liabilities | -- | -- | $32.9M | $32.4M | $46.8M | |
| Total Liabilities | -- | -- | $155.9M | $146.5M | $163.7M | |
| Total Equity | -- | -- | $127.9M | $71.8M | $15.5M | |
| Total Debt | -- | -- | $79.1M | $85.3M | $91.5M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$71.1M | -$46.4M | -$34.6M | -$8.3M | $819K | |
| Cash From Investing | -$108.2M | $18.4M | $59.6M | $7.7M | $10.4M | |
| Cash From Financing | $229.2M | -$5.9M | -$5.1M | -$756K | -$243K | |
| Free Cash Flow | -$75.5M | -$52.1M | -$37.5M | -$9.2M | $1.2M | |
TOI
Sector
Market Cap
$20.1M
$46.5M
Price % of 52-Week High
10.64%
47.23%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
-86.9%
-31.38%
Beta (5-Year)
--
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$0.21
200-day SMA
Sell
Level
$0.58
Bollinger Bands (100)
Sell
Level
0.21 - 0.37
Chaikin Money Flow
Sell
Level
-45M
20-day SMA
Buy
Level
$0.20
Relative Strength Index (RSI14)
Buy
Level
62.88
ADX Line
Buy
Level
30.96
Williams %R
Neutral
Level
-22.7715
50-day SMA
Buy
Level
$0.24
MACD (12, 26)
Sell
Level
0.00
25-day Aroon Oscillator
Buy
Level
32
On Balance Volume
Sell
Level
-16.6M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.5876)
Sell
CA Score
(Annual)
Level (-1.924)
Buy
Beneish M-Score
(Annual)
Level (-3.5313)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (3.1995)
Sell
Piotroski F Score
(Annual)
Level (3)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
The Oncology Institute Inc offers oncology services committed to improving cancer prevention, diagnosis, treatment, research, and education. The company provides services including infusion centres. In-house dispensary, Outpatient blood transfusion, Outpatient stem cell transplant, financial counseling, clinical trials, comprehensive lab testing, and end-of-life counseling. The business operates in three operating segments dispensary, patients services and clinical trials and others. Key revenue is earned from providing patient services.
Stock Forecast FAQ
In the current month, TOI has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The TOI average analyst price target in the past 3 months is --.
-
Where Will The Oncology Institute Stock Be In 1 Year?
According to analysts, the consensus estimate is that The Oncology Institute share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About The Oncology Institute?
Analysts are divided on their view about The Oncology Institute share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that The Oncology Institute is a Sell and believe this share price will drop from its current level to --.
-
What Is The Oncology Institute's Price Target?
The price target for The Oncology Institute over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is TOI A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for The Oncology Institute is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of TOI?
You can purchase shares of The Oncology Institute via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase The Oncology Institute shares.
-
What Is The The Oncology Institute Share Price Today?
The Oncology Institute was last trading at $0.26 per share. This represents the most recent stock quote for The Oncology Institute. Yesterday, The Oncology Institute closed at $0.27 per share.
-
How To Buy The Oncology Institute Stock Online?
In order to purchase The Oncology Institute stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
How High Will Airbnb Stock Go?
Airbnb, Inc. (NASDAQ:ABNB) share price has seen substantial turbulence over…
Why Is SoundHound AI Stock Up So Much?
Like many companies improving AI technologies and exploring ways to…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 43x
Buy
56
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Buy
57
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
64
ARQQ alert for Dec 27
Arqit Quantum [ARQQ] is down 3.03% over the past day.
Buy
64
QMCO alert for Dec 27
Quantum [QMCO] is up 2.91% over the past day.
Buy
65
ALGS alert for Dec 27
Aligos Therapeutics [ALGS] is down 4.4% over the past day.
